| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 01/03/2023 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to buy) | 10k | $0.00 | $0 | | 01/03/2023 |
| 12/15/2022 | ARCA biopharma, Inc. | ABIO | Grant | Stock Option (right to buy) | 6k | $2.32 | $13.9k | | 12/15/2022 |
| 01/03/2022 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to buy) | 10k | $0.00 | $0 | | 01/03/2022 |
| 09/23/2021 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 15k | $10.08 | $151.2k | By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust | 09/23/2021 |
| 09/23/2021 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Sale | Common Stock | 15k | $10.08 | $151.2k | By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust | 09/23/2021 |
| 09/21/2021 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 10k | $9.80 | $98k | By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust | 09/21/2021 |
| 05/12/2021 | ARCA biopharma, Inc. | ABIO | Purchase | Common Stock | 10k | $3.19 | $31.9k | | 05/13/2021 |
| 01/12/2021 | ARCA biopharma, Inc. | ABIO | Grant | Stock Option (right to buy) | 12k | $4.31 | $51.7k | | 01/12/2021 |
| 01/04/2021 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to buy) | 7.6k | $0.00 | $0 | | 01/04/2021 |
| 12/18/2020 | ARCA biopharma, Inc. | ABIO | Purchase | Common Stock | 10k | $4.16 | $41.6k | | 12/18/2020 |
| 11/19/2020 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 10k | $8.03 | $80.3k | By Robert E. Conway Rev Trust and Carolyn J. Conway Rev Trust | 11/19/2020 |
| 09/25/2020 | ARCA biopharma, Inc. | ABIO | Purchase | Common Stock | 5k | $4.28 | $21.4k | | 09/25/2020 |
| 09/22/2020 | ARCA biopharma, Inc. | ABIO | Purchase | Common Stock | 3.1k | $4.66 | $14.2k | | 09/22/2020 |
| 09/21/2020 | ARCA biopharma, Inc. | ABIO | Purchase | Common Stock | 10k | $4.77 | $47.7k | | 09/21/2020 |
| 01/02/2020 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to buy) | 7.6k | $0.00 | $0 | | 01/02/2020 |
| 01/02/2019 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to buy) | 7.6k | $0.00 | $0 | | 01/02/2019 |
| 03/01/2018 | ARCA biopharma, Inc. | ABIO | Grant | Stock Option (right to buy) | 8k | $0.72 | $5.8k | | 03/01/2018 |
| 01/02/2018 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to buy) | 7.6k | $0.00 | $0 | | 01/02/2018 |
| 05/09/2017 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 5k | $2.34 | $11.7k | | 05/09/2017 |
| 05/08/2017 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 15k | $2.28 | $34.2k | | 05/08/2017 |
| 05/05/2017 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 20k | $2.30 | $46k | | 05/05/2017 |
| 05/04/2017 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 10k | $2.26 | $22.6k | | 05/04/2017 |
| 03/24/2017 | ARCA biopharma, Inc. | ABIO | Purchase | Common Stock | 25k | $2.59 | $64.8k | | 03/24/2017 |
| 09/12/2016 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to Buy) | 12.3k | $0.00 | $0 | | 09/12/2016 |
| 12/09/2015 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 10k | $8.10 | $81k | | 12/09/2015 |
| 09/11/2015 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to Buy) | 7.6k | $0.00 | $0 | | 09/11/2015 |
| 07/16/2015 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Grant | Stock Option (Right to Buy) | 11.5k | $0.00 | $0 | | 07/16/2015 |
| 02/11/2014 | ARCA biopharma, Inc. | ABIO | Grant | Stock Option (right to buy) | 8k | $1.80 | $14.4k | | 02/11/2014 |
| 09/17/2013 | ARCA biopharma, Inc. | ABIO | Grant | Stock Option (right to buy) | 14.8k | $1.38 | $20.4k | | 09/17/2013 |
| 09/17/2013 | ARCA biopharma, Inc. | ABIO | Grant | Stock Option (right to buy) | 2.6k | $1.38 | $3.6k | | 09/17/2013 |
| 10/04/2011 | ARRAY BIOPHARMA INC | ARRY | Grant | Common Stock | 57.2k | $0.00 | $0 | | 10/04/2011 |
| 06/17/2011 | ARRAY BIOPHARMA INC | ARRY | Purchase | Common Stock | 25k | $2.17 | $54.2k | | 06/17/2011 |